Ascendis’ TransCon Positioned To Take On BioMarin’s Voxzogo

Ascendis Pharma A/S is preparing to file a new drug application for TransCon CNP (navepegritide) early next year for treatment of the growth condition achondroplasia after announcing positive results from the Phase III ApproaCH trial on 16 September.

TransCon CNP is intended to rival to BioMarin Pharmaceutical Inc.’s Voxzogo (vosoritide), which was granted accelerated approval by the US Food and Drug Administration for achondroplasia in 2021 and is the lynchpin of BioMarin’s growth strategy